University of Birmingham

Three-way DNA junctions are recognizable by drugs

Published in Law and Health Weekly, March 18th, 2006

A team of scientists has developed a synthetic drug agent that targets and binds to the centre of a three-way junction in the DNA- a crucial step forward for researchers who are developing drugs to combat cancer and other diseases.

The work was led by Mike Hannon at the University of Birmingham, U.K., and Miquel Coll at the Spanish Research Council in Barcelona.

DNA contains the information which encodes life itself; its double-helical structure was recognized 50 years ago. Scientists soon started designing drugs to target DNA and used them to treat diseases such as cancer, viral infections, and sleeping sickness. In the 1960s, scientists discovered...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2006-03-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry